DNMT3A and Miyoshi myopathy: In MM, increased DNMT3A/B levels in MM patients compared to patients with the premalignant condition monoclonal gammopathy of undetermined significance (MGUS) due to miR29a/b downregulation have been reported and miR-29b mimics were shown to inhibit MM cell growth and promote cell killing by bortezomib and CD8 + T cells [20, 21].